Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 253 recommendations for 85 medicines and 5 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
6.2. Antibacterials
  1. Amikacin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    • Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    First choice
    Neutropenia (high-risk) co-prescribed with cefotaxime Inflammatory and other diseases of prostate (severe) co-prescribed with cefotaxime Acute pyelonephritis (severe) co-prescribed with ceftriaxone Inflammatory and other diseases of prostate (severe) co-prescribed with ceftriaxone Acute pyelonephritis (severe)
    Second choice
    co-prescribed with cloxacillin Sepsis without septic shock
    Section
    Antituberculosis medicines
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  2. Amoxicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    • Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)
    Indications
    First choice
    Acute pharyngitis Periapical abscess without sinus Acute sinusitis Acute otitis media Chronic obstructive pulmonary disease with acute exacerbation Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Sepsis without septic shock
    Second choice
    Bacterial meningitis
  3. Amoxicillin + clavulanic acid General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
    • Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    First choice
    Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Infectious cystitis Neutropenia (low-risk) Other specified pneumonia (Hospital-acquired pneumonia) Bacterial cellulitis, erysipelas or lymphangitis Peritonitis (mild-moderate) Acute sinusitis Peritoneal abscess (mild-moderate) Chronic obstructive pulmonary disease with acute exacerbation
    Second choice
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) Bacterial infection of joint Other specified prophylactic measures Osteomyelitis or osteitis Acute otitis media
    Section
    Antituberculosis medicines
    • Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  4. Ampicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
    Indications
    First choice
    Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Peritonitis (mild-moderate) Peritonitis (severe) Peritoneal abscess (mild-moderate) Peritoneal abscess (severe) co-prescribed with gentamicin Sepsis without septic shock
    Second choice
    Bacterial meningitis
  5. Azithromycin General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)
    Indications
    First choice
    Trachoma Cholera Cholera [children] Paratyphoid fever Chlamydia trachomatis Typhoid fever Yaws co-prescribed with ceftriaxone Gonococcal infection
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with cefixime Gonococcal infection
  6. Bedaquiline General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 100 mg tablet; 20 mg tablet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  7. Benzathine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection
    Indications
    First choice
    Congenital syphilis [children] Syphilis
  8. Benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
    Indications
    First choice
    Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Congenital syphilis [children] Syphilis Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Sepsis without septic shock
    Second choice
    Bacterial meningitis
  9. Cefalexin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
    • Oral > Solid > dispersible tablet: 125 mg; 250 mg
    Indications
    First choice
    Bacterial cellulitis, erysipelas or lymphangitis
    Second choice
    Chronic obstructive pulmonary disease with acute exacerbation Acute pharyngitis
  10. Cefazolin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
    Indications
    First choice
    Other specified prophylactic measures Other specified prophylactic measures
    Second choice
    Bacterial infection of joint Osteomyelitis or osteitis
  11. Cefiderocol General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  12. Cefixime General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
    Indications
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent Gonococcal infection
  13. Cefotaxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    First choice
    Bacterial meningitis Inflammatory and other diseases of prostate (severe) Acute pyelonephritis (severe) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Bacterial pneumonia (Community-acquired pneumonia - severe) Peritoneal abscess (mild-moderate) Peritoneal abscess (severe) Other specified pneumonia (Hospital-acquired pneumonia) Peritonitis (mild-moderate) Peritonitis (severe)
    Second choice
    Inflammatory and other diseases of prostate (mild to moderate) Acute pyelonephritis (mild to moderate) Sepsis without septic shock Bacterial infection of joint Osteomyelitis or osteitis
  14. Ceftazidime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
    Indications
    First choice
    Endophthalmitis
    Other indications
    Pseudomonas aeruginosa resistant to other antibiotic
  15. Ceftazidime + avibactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  16. Ceftolozane + tazobactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa
  17. Ceftriaxone General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial
    Indications
    First choice
    Inflammatory and other diseases of prostate (severe) Bacterial meningitis Acute pyelonephritis (severe) Other specified pneumonia (Hospital-acquired pneumonia) Paratyphoid fever Typhoid fever Peritonitis (mild-moderate) Peritonitis (severe) Peritoneal abscess (mild-moderate) Peritoneal abscess (severe) Gonococcal infection Endophthalmitis Bacterial pneumonia (Community-acquired pneumonia - severe) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with metronidazole Necrotising fasciitis
    Second choice
    Inflammatory and other diseases of prostate (mild to moderate) Acute pyelonephritis (mild to moderate) Infectious gastroenteritis or colitis without specification of infectious agent Bacterial infection of joint Sepsis without septic shock Osteomyelitis or osteitis
  18. Cefuroxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
    Indications
    Second choice
    Other specified prophylactic measures
  19. Chloramphenicol General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    Indications
    Second choice
    Bacterial meningitis
  20. Ciprofloxacin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
    • Oral > Liquid: 250 mg per 5 mL (anhydrous)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
    Indications
    First choice
    Acute pyelonephritis (mild to moderate) Infectious gastroenteritis or colitis without specification of infectious agent Paratyphoid fever Typhoid fever Neutropenia (low-risk) Inflammatory and other diseases of prostate (mild to moderate)
    Second choice
    Cholera Cholera [children] Peritonitis (mild-moderate) Peritoneal abscess (mild-moderate)
  21. Clarithromycin General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    • Oral > Solid > dosage form: 500 mg; 250 mg
    • Oral > Solid > dosage form: 500 mg
    Indications
    First choice
    co-prescribed with cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe)
    Second choice
    Acute pharyngitis co-prescribed with amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe)
    Other indications
    Helicobacter pylori associated gastric ulcer
  22. Clindamycin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
    • Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    Indications
    First choice
    Necrotising fasciitis
    Second choice
    Bacterial infection of joint Osteomyelitis or osteitis
  23. Clofazimine General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
    Section
    Antileprosy medicines
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    Leprosy
  24. Cloxacillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
    • Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)
    Indications
    First choice
    Osteomyelitis or osteitis Bacterial infection of joint Bacterial cellulitis, erysipelas or lymphangitis
    Second choice
    co-prescribed with amikacin Sepsis without septic shock
  25. Colistin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  26. Cycloserine General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dosage form: 250 mg; 125 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  27. Dapsone General information
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
    Indications
    Leprosy
  28. Delamanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 25 mg
    • Oral > Solid > tablet: 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  29. Doxycycline General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    • Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
    • Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
    • Oral > Solid > dosage form: 100 mg (as hyclate)
    Indications
    First choice
    Cholera Chlamydia trachomatis
    Second choice
    Cholera [children] Chronic obstructive pulmonary disease with acute exacerbation Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
  30. Erythromycin General information
    Section
    Watch group antibiotics
    Indications
    Second choice
    Therapeutic equivalent to clarithromycin for Acute pharyngitis
  31. Ethambutol General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)
    Indications
    Tuberculosis
  32. Ethambutol + isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  33. Ethambutol + isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 150 mg tablet
    Indications
    Tuberculosis
  34. Ethionamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 125 mg
    • Oral > Solid > tablet: 250 mg
    Indications
    Tuberculous meningitis Multi-drug resistant Mycobacterium tuberculosis
  35. Fosfomycin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  36. Gentamicin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
    Indications
    First choice
    Neonatal meningitis Sepsis without septic shock Sepsis without septic shock Sepsis without septic shock co-prescribed with amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with ampicillin Peritonitis (mild-moderate) co-prescribed with ampicillin Peritonitis (severe) co-prescribed with ampicillin Peritoneal abscess (mild-moderate) co-prescribed with ampicillin Peritoneal abscess (severe) co-prescribed with ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choice
    Gonococcal infection Other specified prophylactic measures
  37. Imipenem + cilastatin General information
    Section
    Watch group antibiotics
    Indications
    Second choice
    Therapeutic equivalent to meropenem for Peritonitis (severe) Therapeutic equivalent to meropenem for Peritoneal abscess (severe) Therapeutic equivalent to meropenem for Neutropenia (high-risk)
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to meropenem for Multi-drug resistant Mycobacterium tuberculosis
  38. Isoniazid General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 100 mg (scored)
    • Oral > Solid > tablet: 100 mg; 300 mg
    Indications
    Tuberculosis
  39. Isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg
    Indications
    Tuberculosis
  40. Isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 50 mg + 75 mg
    • Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg
    Indications
    Tuberculosis
  41. Isoniazid + rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 300 mg + 300 mg tablet (scored)
    Indications
    Latent tuberculosis
  42. Levofloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 250 mg; 500 mg; 750 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  43. Linezolid General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 600 mg
    Indications
    Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 150 mg (scored)
    • Oral > Solid > tablet: 600 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  44. Meropenem General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Second choice
    Neonatal meningitis Peritonitis (severe) Peritoneal abscess (severe) Neutropenia (high-risk)
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  45. Meropenem + vaborbactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii
  46. Metronidazole General information
    Section
    Access group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Local > Rectal > Suppository: 500 mg; 1 g
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
    • Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
    • Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg
    Indications
    First choice
    Intestinal infections due to Clostridioides difficile Trichomoniasis Necrotising fasciitis co-prescribed with cefazolin Other specified prophylactic measures co-prescribed with cefotaxime Peritoneal abscess (mild-moderate) co-prescribed with cefotaxime Peritoneal abscess (severe) co-prescribed with cefotaxime Peritonitis (mild-moderate) co-prescribed with cefotaxime Peritonitis (severe) co-prescribed with ceftriaxone Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritoneal abscess (severe) co-prescribed with ceftriaxone Peritonitis (mild-moderate) co-prescribed with ceftriaxone Peritonitis (severe)
    Second choice
    co-prescribed with ciprofloxacin Peritoneal abscess (mild-moderate) co-prescribed with ciprofloxacin Peritonitis (mild-moderate)
  47. Moxifloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 400 mg
    • Oral > Solid > dispersible tablet: 100 mg
    Indications
    Tuberculosis Multi-drug resistant Mycobacterium tuberculosis
  48. Nitrofurantoin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL oral liquid
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    First choice
    Infectious cystitis
  49. P-aminosalicylate sodium General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  50. Phenoxymethylpenicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
    Indications
    First choice
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Periapical abscess without sinus Acute pharyngitis
  51. Piperacillin + tazobactam General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
    Indications
    First choice
    Neutropenia (high-risk) Other specified pneumonia (Hospital-acquired pneumonia) Peritonitis (severe) Peritoneal abscess (severe) co-prescribed with clindamycin Necrotising fasciitis
  52. Plazomicin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg per 10 mL
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  53. Polymyxin B (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  54. Pretomanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 200 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  55. Procaine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
    Indications
    First choice
    Congenital syphilis [children]
    Second choice
    Syphilis
  56. Protionamide General information
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to ethionamide for Multi-drug resistant Mycobacterium tuberculosis
  57. Pyrazinamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 400 mg; 500 mg
    Indications
    Tuberculosis
  58. Rifabutin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg
    Indications
    Tuberculosis
  59. Rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Tuberculosis
    Section
    Antileprosy medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Leprosy
  60. Rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 150 mg; 300 mg
    • Oral > Solid > dispersible tablet: 150 mg
    Indications
    Tuberculosis Latent tuberculosis
  61. Spectinomycin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection
    Indications
    Second choice
    Gonococcal infection
  62. Streptomycin (injection) General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  63. Sulfamethoxazole + trimethoprim General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
    Indications
    First choice
    Infectious cystitis
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent
  64. Tedizolid General information
    Section
    Reserve group antibiotics
    Indications
    Therapeutic equivalent to linezolid for Methicillin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Enterococcus
  65. Terizidone General information
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to cycloserine for Multi-drug resistant Mycobacterium tuberculosis
  66. Trimethoprim General information
    Section
    Access group antibiotics
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 100 mg; 200 mg
    Indications
    First choice
    Infectious cystitis
  67. Vancomycin General information
    Section
    Watch group antibiotics
    • Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    • Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    Indications
    First choice
    Necrotising fasciitis co-prescribed with ceftazidime Endophthalmitis co-prescribed with ceftriaxone Endophthalmitis
    Second choice
    Intestinal infections due to Clostridioides difficile Neutropenia (high-risk)